Referred to the House Committee on Energy and Commerce.
The bill amends section 505(j) of the Federal Food, Drug, and Cosmetic Act (the abbreviated new drug application pathway for generics) to add specific requirements for generic drugs that are intended for use with a device. It requires applicants to submit ‘‘relevant information as determined by the Secretary’’ to support that the generic drug used with a device can be expected to have the same clinical effect and safety profile as the listed drug used with its device, and it expressly lists examples of information the FDA may consider (device performance, compatibility, delivery, comparative analyses, user-interface differences, and human factors studies).
Safety versus access: liberals emphasize patient safety and human factors; conservatives emphasize risks that new requirements will delay generics and raise prices.
Relative to its intended legislative type, this bill amends 21 U.S.C. 355(j) to add explicit evidentiary requirements and an insufficiency ground for abbreviated new drug applications when the listed drug is intended for use with a device, specifying types of comparative and human factors information and delegating determinations to the Secretary.
The bill amends section 505(j) of the Federal Food, Drug, and Cosmetic Act (the abbreviated new drug application pathway for generics) to add specific requirements for generic drugs that are intended for use with a device.
It requires applicants to submit ‘‘relevant information as determined by the Secretary’’ to support that the generic drug used with a device can be expected to have the same clinical effect and safety profile as the listed drug used with its device, and it expressly lists examples of information the FDA may consider (device performance, compatibility, delivery, comparative analyses, user-interface differences, and human factors studies).
The amendment also clarifies that if an application for a listed drug intended for use with a device lacks sufficient information to support equivalence, that insufficiency is a statutory consideration.
On content alone, this is a moderate‑sized, technical but consequential regulatory change that could be justified on safety grounds and therefore attract some bipartisan sympathy; however, it imposes new evidentiary burdens that create clear winners and losers among well‑organized industry stakeholders. The absence of compromise mechanisms (e.g., phased implementation) and likely pushback from generic manufacturers make enactment uncertain without negotiated amendments or stakeholder deals.
Relative to its intended legislative type, this bill amends 21 U.S.C. 355(j) to add explicit evidentiary requirements and an insufficiency ground for abbreviated new drug applications when the listed drug is intended for use with a device, specifying types of comparative and human factors information and delegating determinations to the Secretary.
Safety versus access: liberals emphasize patient safety and human factors; conservatives emphasize risks that new requirements will delay generics and raise prices.
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety versus access: liberals emphasize patient safety and human factors; conservatives emphasize risks that new requirements will delay generics and raise prices.
A mainstream progressive would likely view the bill as an effort to improve patient safety for drug-device combinations while having mixed feelings about potential impacts on the affordability and timely availability of generics.
They will welcome explicit attention to device compatibility, delivery, and human factors because those issues affect clinical safety, adherence, and equitable outcomes.
At the same time they will be cautious that additional evidentiary requirements could delay generic entry and keep prices high unless the FDA implements the rule to avoid unnecessary burdens.
A pragmatic, moderate observer would see this as a technical, targeted change to the ANDA process intended to ensure clinical equivalence when drugs are used with delivery devices.
They will generally favor improved clarity for regulators and industry but will be concerned about potential unintended consequences — namely increased review time, greater developer costs, and legal friction over what ‘‘relevant information as determined by the Secretary’’ means.
Centrists will lean toward conditional support if the bill is accompanied by process safeguards (timelines, guidance) that minimize delays and unnecessary data burdens.
A mainstream conservative would be skeptical of new statutory language that appears to broaden FDA’s discretion and evidentiary demands for generics used with devices.
They would be concerned the bill creates additional regulatory burden and could inadvertently protect incumbent brand manufacturers by making generic approvals harder or slower.
Conservatives favor competition and lower prices, and if this measure increases approval costs or gives FDA wide latitude without clear limits, they are likely to oppose or seek substantial narrowing amendments that protect speedy market entry.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, this is a moderate‑sized, technical but consequential regulatory change that could be justified on safety grounds and therefore attract some bipartisan sympathy; however, it imposes new evidentiary burdens that create clear winners and losers among well‑organized industry stakeholders. The absence of compromise mechanisms (e.g., phased implementation) and likely pushback from generic manufacturers make enactment uncertain without negotiated amendments or stakeholder deals.
The bill has not accumulated any surfaced votes yet.
Safety versus access: liberals emphasize patient safety and human factors; conservatives emphasize risks that new requirements will delay g…
On content alone, this is a moderate‑sized, technical but consequential regulatory change that could be justified on safety grounds and the…
Relative to its intended legislative type, this bill amends 21 U.S.C. 355(j) to add explicit evidentiary requirements and an insufficiency ground for abbreviated new drug applications when the listed drug is intended fo…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.